FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
The U.S. Food and Drug Administration announced on March 3, 2026 the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misb[...]